01 Dec 2020 TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic Leukemia
01 Dec 2020 MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
01 Dec 2020 Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404
01 Dec 2020 Junshi Biosciences Announces Dosing of First Patient in Phase I Study of Anti-TROP2 Antibody -TUB196 Conjugate
01 Dec 2020 Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis
01 Dec 2020 SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19
01 Dec 2020 Zymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer
27 Nov 2020 AbbVie and Eisai Announce an approval for additional indication of HUMIRA®, a fully Human Anti-TNFα Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world
26 Nov 2020 FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma
26 Nov 2020 Celltrion completes enrolment for global Phase II clinical trial with COVID-19 treatment candidate CT-P59
26 Nov 2020 Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)
25 Nov 2020 Integral Molecular Announces Best-in-Class Antibodies Against Complex Oncology Target Claudin 18.2
25 Nov 2020 F-star Therapeutics Announces Clearance of Clinical Trial Application for FS222
25 Nov 2020 European Commission Approves Janssen’s TREMFYA (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)
25 Nov 2020 Genmab Announces Enapotamab Vedotin Update
24 Nov 2020 Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
23 Nov 2020 Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors
23 Nov 2020 Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies
23 Nov 2020 Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma
22 Nov 2020 Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
20 Nov 2020 Alvotech Announces That the U.S. FDA and EMA Have Accepted Regulatory Submissions for AVT02, a Proposed Biosimilar to HUMIRA® (adalimumab)
20 Nov 2020 BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma
20 Nov 2020 SynOx Therapeutics raises €37M in Series A Financing
20 Nov 2020 Imfinzi approved in the US for less-frequent, fixed-dose use
20 Nov 2020 Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up